**Supplementary Table 1:** Characteristics, symptoms, and initial Abbott’s BinaxNOW antigen test results for SARS-CoV-2 in persons providing nasal swabs (N = 2,110) – Oshkosh, Wisconsin, November 16 - December 15, 2020a

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Overall****(n=2,110)** | **BinaxNOW Positive (n=265)** | **BinaxNOW Negative (n=1,845)** | **p-value** |
| **Sex** |  |  |  | 0.45 |
| Female | 1,183 (56.1%) | 139 (52.5%) | 1,044 (56.6%) |  |
| Male | 905 (42.9%) | 123 (46.4%) | 782 (42.4%) |  |
| Unknown | 22 (1.0%) | 3 (1.1%) | 19 (1.0%) |   |
| **Age (years)** |  |  |  |  0.12 |
| 5 to 11 | 88 (4.2%) | 9 (3.4%) | 79 (4.3%) |  |
| 12 to 17 | 137 (6.5%) | 16 (6.0%) | 121 (6.6%) |  |
| 18 to 29 | 395 (18.7%) | 51 (19.2%) | 344 (18.6%) |  |
| 30 to 39 | 368 (17.4%) | 45 (17.0%) | 323 (17.5%) |  |
| 40 to 49 | 331 (15.7%) | 32 (12.1%) | 299 (16.2%) |  |
| 50 to 64 | 579 (27.4%) | 92 (34.7%) | 487 (26.4%) |  |
| 65 to 74 | 168 (8.0%) | 14 (5.3%) | 154 (8.3%) |  |
| 75 to 84 | 41 (1.9%) | 5 (1.9%) | 36 (2.0%) |  |
| ≥85 | 3 (0.1%) | 1 (0.4%) | 2 (0.1%) |  |
| **Ethnicity** |  |  |  | 0.37 |
| Non-Hispanic or Latino | 1,952 (92.5%) | 242 (91.3%) | 1,710 (92.7%) |  |
| Hispanic or Latino | 66 (3.1%) | 12 (4.5%) | 54 (2.9%) |  |
| Unknown | 92 (4.4%) | 11 (4.2%) | 81 (4.4%) |  |
| **Race** |  |  |  | 0.31 |
| White | 2,002 (94.9%) | 256 (96.6%) | 1,746 (94.6%) |  |
| Otherb | 62 (2.9%) | 5 (1.9%) | 57 (3.1%) |  |
| Multiple | 28 (1.3%) | 1 (0.4%) | 27 (1.5%) |  |
| Unknown | 18 (0.9%) | 3 (1.1%) | 15 (0.8%)  |  |
| **Oshkosh City Resident**c | 819 (38.8%) | 81 (30.6%) | 738 (40.0%) | 0.01 |
| **Healthcare Provider**d | 190 (9.0%) | 22 (8.3%) | 168 (9.1%) | 0.91 |
| **University Affiliation**e | 185 (8.8%) | 17 (6.4%) | 168 (9.1%) | 0.31 |
| **Close Contact in Past 14 Days** |  |  |  | <0.01 |
| Yes | 894 (42.4%) | 150 (56.6%) | 744 (40.3%) |  |
| No | 841 (39.9%) | 62 (23.4%) | 779 (42.2%) |  |
| Unknown | 375 (17.8%) | 53 (20.0%) | 322 (17.5%) |  |
|  **Current Symptoms**f |  |  |  | <0.01 |
| Yes | 1,188 (56.3%) | 223 (84.2%) | 965 (52.3%) |  |
| No | 877 (41.6%) | 38 (14.3%) | 839 (45.5%) |  |
| Unknown | 45 (2.1%) | 4 (1.5%) | 41 (2.2%) |  |
| **Current Symptoms** |  |  |   |  |
| Congestion/Rhinorrhea | 668 (31.7%) | 138 (52.1%) | 530 (28.7%) | <0.01 |
| Headache | 506 (24.0%) | 90 (34.0%) | 416 (22.5%) | <0.01 |
| Sore throat | 412 (19.5%) | 68 (25.7%) | 344 (18.6%) | <0.01 |
| Cough | 388 (18.4%) | 101 (38.1%) | 287 (15.6%) | <0.01 |
| Fatigue | 388 (18.4%) | 73 (27.5%) | 315 (17.1%) | <0.01 |
| Muscle Aches | 280 (13.3%) | 72 (27.2%) | 208 (11.3%) | <0.01 |
| Chills | 154 (7.3%) | 37 (14.0%) | 117 (6.3%) | <0.01 |
| Shortness of Breath | 127 (6.0%) | 19 (7.2%) | 108 (5.9%) | 0.48 |
| Loss of Smell  | 106 (5.0%) | 61 (23.0%) | 45 (2.4%) | <0.01 |
| Diarrhea | 107 (5.0%) | 14 (5.3%) | 93 (5.0%) | 0.99 |
| Fever | 95 (4.5%) | 36 (13.6%) | 59 (3.2%) | <0.01 |
| Nausea/Vomiting | 95 (4.5%) | 13 (4.9%) | 82 (4.4%) | 0.86 |
| Loss of Taste | 92 (4.4%) | 48 (18.1%) | 44 (2.4%) | <0.01 |
| Abdominal Pain | 56 (2.7%) | 8 (3.0%) | 48 (2.6%) | 0.85 |
| Rigors | 1 (0.0%) | 0 | 1 (0.0%) | 1.0 |
| Otherg  | 47 (2.2%) | 11 (4.2%) | 36 (2.0%) | 0.04 |

aThis includes encounters where paired BinaxNOW tests and RT-PCR results were collected. Demographic data from 86 encounters were from repeat individuals.

bIncludes Black, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander.

cResidency information was available for 2,109 encounters included in the denominator.

dHealthcare occupation information was available for 2,095 encounters included in the denominator.

eIncludes faculty, students, and employees of a university and this data was available for 2,088 encounters included in the denominator.

fDefined as ≥ 1 current reported symptom from any of 15 symptom criteria for the COVID-19 case definition by the Council of State and Territorial Epidemiologists (CSTE). https://www.cste.org/news/520707/CSTE-Interim-Position-Statement-Update-to-COVID-19-Case-Definition.htm

gFor encounters with none of the 15 listed CSTE symptoms reported, other symptoms included chest pain, throat swelling, ear pain, hoarse voice, and rash.

**Supplementary Figure 1:** Real-time reverse transcription–polymerase chain reaction (RT-PCR)a SARS-CoV-2 threshold cycle valuesb for 334 specimens collected in a community setting, stratified by the initial BinaxNOW antigen test status – Oshkosh, Wisconsin, November 16 - December 15, 2020 

aA three viral target RT-PCR assay was used. TaqPath SARS-CoV-2 Combo Kit. https://www.fda.gov/media/136112/download

bFor all specimens that met the criteria for RT-PCR positivity by this assay, we plotted the threshold cycle for the N gene (one of the three targets).

**Supplementary Figure 2:** Real-time reverse transcription–polymerase chain reaction (RT-PCR)a SARS-CoV-2 threshold cycle valuesb for 329 specimens collected in a community setting, stratified by symptom statusc – Oshkosh, Wisconsin, November 16 - December 15, 2020



aA three viral target RT-PCR assay was used. TaqPath SARS-CoV-2 Combo Kit. https://www.fda.gov/media/136112/download

bFor all specimens that met the criteria for RT-PCR positivity by this assay, we plotted the threshold cycle for the N gene (one of the three targets).

cDefined as ≥ 1 current reported symptom from any of 15 symptom criteria for the COVID-19 case definition by the Council of State and Territorial Epidemiologists. https://www.cste.org/news/520707/CSTE-Interim-Position-Statement-Update-to-COVID-19-Case-Definition.htm